Abstracts tagged "Autoantibodies and statin-induced myopathies"

Abstract Number: 945 • 2015 ACR/ARHP Annual Meeting
Anti-Hmgcr Antibodies As Specific Marker for Immune Mediated Necrotizing Myopathies
Lucile Musset¹, Chelsea Bentow², Marvin J. Fritzler³, Jiri Vencovsky⁴, Olivier Benveniste⁵, Ignacio Garcia de la Torre⁶, Franco Franceschini⁷, Katalin Danko⁸, Qinglin Peng⁹, Sophie Hue¹⁰, Olivier Boyer¹¹, Nicola Bizzaro¹², Yoshinao Muro¹³, Xavier Bossuyt¹⁴, Anna Ghirardello¹⁵ and Michael Mahler¹⁶, ¹Immunology, Immunochemistry & Autoimmunity Laboratory, Pitié-Salpêtrière University Hospital, Paris, France, ²Research, Inova Diagnostics, San Diego, CA, ³Medicine, University of Calgary, Calgary, AB, Canada, ⁴Institute of Rheumatology, Charles University, Prague, Czech Republic, ⁵Department de Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, ⁶Hospital General de Occidente, Zapopan, Mexico, ⁷Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁸Division of Clinical Immunology, 3rd Department of Internal Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary, Co-Author, Debrecen, Hungary, ⁹Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China, ¹⁰CHU Henri Mondor, APHP, Créteil, France, ¹¹Immunology, INSERM, U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen University Hospital, Rouen, France, ¹²Laboratory of Clinical Pathology, San Antonio Hospital, Tolmezzo, Italy, ¹³Dermatology, Division of Connective Tissue Disease & Autoimmunity, Nagoya University Graduate School of Medicine, Nagoya, Japan, ¹⁴Laboratory Medicine, University Hospitals Leuven, and Department of Microbiology and Immunology, Catholic University of Leuven, Leuven, Belgium, ¹⁵Department of Medicine-DIMED, University of Padova, Padova, Italy, ¹⁶Inova Diagnostics, San Diego, CA
Background/Purpose :Autoantibodies are important biomarkers in the diagnosis of idiopathic inflammatory myopathies (IIM) including polymyositis (PM) and dermatomyositis (DM), inclusion body myositis (IBM) as well…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].